What Is the Best CYP3A4 Inhibitors List for Safer Interaction Checks

Why Does a CYP3A4 Inhibitors List Matter for Chemical and Pharma Work?

A working CYP3A4 inhibitors list helps you catch drug interaction risk before a formulation file, sourcing record, research note, or regulatory check goes too far. For more chemical inhibitor topics, you can browse the inhibitors category. This article is for technical reference only, not personal medical advice. Final calls should come from approved labels, clinicians, pharmacists, and study data that has been checked.

A High-Use Metabolic Enzyme

CYP3A4 is one of the main human drug-metabolizing enzymes, mainly in the liver and intestine. Peer-reviewed reviews available up to 2024 often put CYP3A4 and CYP3A5 involvement at about 30% to 50% of clinically used drugs.

That range is not a small detail for sourcing, formulation, or DDI review. If a compound blocks CYP3A4, a sensitive substrate may remain in the body longer than planned.

Exposure Changes That Are Easy to Miss

The number people usually check first is AUC, or area under the concentration-time curve. FDA’s healthcare professional interaction table, checked in July 2026, defines a strong CYP inhibitor as one that raises AUC of a sensitive index substrate by at least 5-fold.

Moderate means 2-fold to less than 5-fold. Weak means 1.25-fold to less than 2-fold. These cutoffs make the discussion easier to use in a review file, instead of leaving it as loose interaction wording.

A List That Still Needs Context

No public CYP3A4 inhibitor list stays complete for long. FDA also says its examples are a guide, not a full list of every drug, food, or supplement that may fit one class.

New labels, oncology drugs, antivirals, and combination products can change the working view. In practice, you use a list as the first screen, then check the current prescribing information before making a decision.

Which Drugs Are Strong CYP3A4 Inhibitors?

Strong inhibitors need a quick flag because they can give the largest exposure increase for sensitive CYP3A substrates. In procurement or quality review, this group is often the one linked with label warnings, dose changes, or avoid-combination wording. It is also the group that makes cautious buyers ask more questions, even when the material is only being checked for research supply.

FDA Potency Cutoff

FDA’s clinical definition is direct: a strong inhibitor raises the AUC of a sensitive index substrate by 5-fold or more. Midazolam and triazolam are listed by FDA as CYP3A index substrates for clinical drug interaction studies.

That is why midazolam data appears so often in development packages. It gives reviewers a practical way to see how much a precipitant drug blocks the CYP3A pathway.

Common Strong Examples

Examples listed by FDA for CYP3A strong inhibition include clarithromycin, itraconazole, ketoconazole, posaconazole, voriconazole, cobicistat, ritonavir, nelfinavir, nefazodone, telithromycin, adagrasib, ceritinib, idelalisib, and several ritonavir-containing antiviral combinations. These names come from different treatment areas.

Because of that, a search limited to only antibiotics or azoles can miss useful items. A buyer or reviewer should check the full name, not only the drug class.

What Strong Usually Means in Practice

Strong does not mean every use is unsafe. It means the combination needs a careful label check before anyone treats it as routine.

A narrow-therapeutic-index substrate, such as certain transplant, oncology, cardiovascular, or sedative drugs, can become a real issue. For a chemical distributor, safer wording is clear and limited: this compound is listed as a strong CYP3A inhibitor in FDA examples, and the user should confirm handling in the applicable label or protocol.

Which Moderate and Weak CYP3A4 Inhibitors Should You Watch?

Moderate and weak inhibitors are sometimes pushed aside, but that is not a good review habit. A moderate inhibitor may still double or triple exposure of a sensitive CYP3A substrate. A weak inhibitor can matter when the patient, substrate, dose, organ function, and transporter profile all move in the wrong direction. Small effects can add up faster than expected.

Moderate Inhibitors Seen in Labels

FDA examples of moderate CYP3A inhibition include aprepitant, ciprofloxacin, conivaptan, crizotinib, diltiazem, dronedarone, erythromycin, fluconazole, grapefruit juice, imatinib, isavuconazole, and verapamil. Fluconazole is a useful example because FDA lists it as a strong CYP2C19 inhibitor and a moderate CYP3A and CYP2C9 inhibitor.

That shows why one compound can sit in more than one pathway bucket. In a real review, checking only one enzyme may leave out part of the interaction picture.

Weak Inhibitors and Borderline Cases

Weak CYP3A inhibitor examples include amiodarone, cimetidine, chlorzoxazone, cilostazol, clotrimazole, cyclosporine, fosaprepitant, fluvoxamine, istradefylline, ivacaftor, lomitapide, ranitidine, ranolazine, selpercatinib, and several newer targeted therapies. Weak does not mean irrelevant.

It means the observed AUC rise is usually smaller by FDA category. The interaction still needs a look if the substrate is sensitive or the patient risk is high.

Grapefruit Juice as a Real-World Example

Grapefruit juice is the non-drug example most people recognize. FDA’s consumer update, current as of July 1, 2021, explains that grapefruit juice can block intestinal CYP3A4, so more of some oral drugs may enter the blood and stay there longer.

FDA also notes that grapefruit does not affect every drug in a class. With some medicines, transporters may even cause the opposite effect, which is why this common example still needs a drug-by-drug check.

How Should You Read the List Without Making a Costly Mistake?

A list is a guide, not the full case file. The same inhibitor can look different across substrates, doses, route of administration, and study designs. For lab teams, one common mistake is treating in vitro inhibitor data and clinical inhibitor categories as the same thing. They are linked, but they are not interchangeable. See also: Flocculants.

Check the Substrate First

Start with one plain question: is the other compound a sensitive CYP3A substrate, a moderately sensitive substrate, or only partly cleared by CYP3A? FDA lists midazolam and triazolam as sensitive CYP3A index substrates.

FDA examples of sensitive CYP3A substrates also include buspirone, avanafil, budesonide, dasatinib, eplerenone, ibrutinib, ivabradine, lurasidone, naloxegol, quetiapine, sildenafil, simvastatin, sirolimus, tacrolimus, and venetoclax. This check should come before judging the inhibitor risk.

Separate In Vitro From Clinical Evidence

For in vitro CYP3A4/5 inhibition, FDA lists azamulin, itraconazole, ketoconazole, troleandomycin, and verapamil as example inhibitors. FDA also warns that many chemical inhibitors are not fully specific for one CYP enzyme.

ICH M12 Drug Interaction Studies, adopted in May 2024 and issued as FDA final guidance in August 2024, also says inhibitor selectivity and potency should be verified under the same experimental conditions with probe substrates. That point matters when a lab result is being used in a customer file or technical reply.

Watch Transporters and Patient Factors

CYP3A rarely works by itself. FDA’s healthcare table often tags the same substance with P-gp, BCRP, OATP1B1, OATP1B3, OCT2, or MATE effects.

Clarithromycin, for example, appears as a strong CYP3A inhibitor and also has transporter entries. Patient factors such as kidney function, liver function, age, inflammation, and co-medication load can change the final risk, so a neat spreadsheet can still miss a complicated case.

How Can You Use This List in Sourcing, Formulation, or Review?

For daily chemical and pharma work, the point is not to memorize every inhibitor. The point is to set up a screen that the team can repeat. You want a short process that catches clear risks, records the source, and leaves space for the specialist review that a final drug label or clinical protocol requires.

Start With a Three-Level Screen

First, classify the inhibitor as strong, moderate, weak, or not reliably classified in public sources. Second, identify whether the paired compound is a sensitive or moderately sensitive CYP3A substrate.

Third, check whether transporter inhibition or induction is also present. This three-level screen catches most early red flags without pretending to replace a full DDI assessment.

Record Source and Date

Write down the source and date beside every classification. A useful note may say FDA healthcare professional CYP examples checked July 2026, or ICH M12 guidance August 2024.

If no reliable public clinical data exists for a research chemical, say that plainly. Do not fill the gap with a guessed category, because that kind of shortcut can travel far in a quotation sheet.

Speak Precisely With Buyers and Labs

Clear wording helps across sales, regulatory, QA, and lab teams. Instead of saying this is dangerous, say the compound is reported as a strong CYP3A inhibitor, and CYP3A-sensitive substrates may show large exposure increases.

If the item is only an in vitro inhibitor, say in vitro. If it is a clinical index inhibitor, say clinical index inhibitor. Simple wording reduces back-and-forth and keeps the technical message under control.

FAQ

Q1: What Is the Short CYP3A4 Inhibitors List to Remember? A: The highest-yield strong examples include clarithromycin, itraconazole, ketoconazole, posaconazole, voriconazole, ritonavir, cobicistat, nelfinavir, nefazodone, telithromycin, ceritinib, idelalisib, and some ritonavir-containing combinations.

Q2: Are All Azole Antifungals Strong CYP3A4 Inhibitors? A: No. FDA examples place itraconazole, ketoconazole, posaconazole, and voriconazole in the strong CYP3A inhibitor group, while fluconazole and isavuconazole are listed as moderate CYP3A inhibitors. Always check the exact compound.

Q3: Is Grapefruit Juice Really a CYP3A4 Inhibitor? A: Yes. FDA describes grapefruit juice as blocking intestinal CYP3A4 for many affected drugs, and FDA’s professional table lists grapefruit juice as a moderate CYP3A inhibitor. The effect still depends on the drug and the person.

Q4: What Is the Difference Between a Strong and Moderate CYP3A4 Inhibitor? A: FDA defines strong as raising AUC of a sensitive index substrate by at least 5-fold. Moderate means an AUC increase of at least 2-fold but less than 5-fold. Weak means at least 1.25-fold but less than 2-fold.

Q5: Can This List Replace a Drug Label or Pharmacist Review? A: No. Use it as an early technical screen. Final decisions should rely on current prescribing information, validated DDI studies, and qualified medical or regulatory review, especially when a sensitive substrate is involved.